SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Leon Neal/Getty Images
Drug Development
GSK, Ionis Present “Potentially Transformative” Data from Hepatitis B Hopeful
GSK and Ionis released promising trial data showing their investigational antisense oligonucleotide, bepirovirsen, could significantly reduce HBsAg and viral DNA levels in patients with CHB.
June 27, 2022
 · 
2 min read
 · 
Tristan Manalac
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
Serious Safety Signal Slows Sarepta’s MOMENTUM in DMD Trial
Sarepta announced that the FDA has put the Phase II trial for its SRP-5051 (vesleteplirsen) for the treatment of patients with DMD on clinical hold following a serious safety signal.
June 24, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
BridgeBio Sees Changes in Key Canavan Disease Markers
BridgeBio released early data from its Phase I/II CANaspire clinical trial, indicating that BBP-812 might be a promising gene therapy for the ultra-rare Canavan disease.
June 23, 2022
 · 
3 min read
 · 
Tristan Manalac
Yuriko Nakao/Getty Images
Business
Galapagos Dives Into Cell Therapy with CellPoint & AboundBio Acquisitions
Galapagos announced that it had acquired CellPoint and AboundBio in an all-cash transaction, greatly expanding its drug portfolio.
June 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Policy
Manufacturing Issues Trip up Acer, Relief in NDA Quest
Acer Therapeutics and Relief Therapeutics announced the FDA has denied their NDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.
June 21, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Scholar Rock Sees Modest Improvements in Phase II SMA Study
Extension data from the Phase II TOPAZ trial showed that apitegromab yielded sustained and continued benefits in non-ambulatory patients with types 2 and 3 spinal muscular atrophy (SMA).
June 20, 2022
 · 
3 min read
 · 
Tristan Manalac
Bodo Marks/picture alliance via Getty Images
Deals
AstraZeneca Rumored to Have Set Sights on Mereo BioPharma Buyout
AstraZeneca appears to have taken an interest in Mereo BioPharma and may be considering a buyout, according to speculations published by The Times UK.
June 17, 2022
 · 
2 min read
 · 
Tristan Manalac
Getty Images
Drug Development
Bavarian Nordic Takes on Pfizer-BioNTech with COVID-19 Booster Candidate
Bavarian Nordic announced that the upcoming Phase III trial for its COVID-19 booster candidate has been redesigned to compete against licensed mRNA-based vaccines.
June 17, 2022
 · 
2 min read
 · 
Tristan Manalac
Image courtesy of Getty Images
Business
ADC Space Continues to Thrive with Four More Companies Linking Up
This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.
June 16, 2022
 · 
3 min read
 · 
Tristan Manalac
2
Policy
Jazz and Redx Tout IND Acceptance while Omega Seeks First
Jazz Pharmaceuticals, Redx Pharma and Omega Therapeutics are pushing forward with their cancer treatments with Investigational New Drug approval and IND application submission.
June 15, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
COVID-19 Research: Paxlovid Disappoints in Standard-Risk Setting, Nasal Spray Offers New Hope
Biopharma has been stepping up research and drug development against COVID-19 -though results haven’t always been encouraging. Here are the latest stories from this space:
June 15, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Soleno Soars on Positive Prader-Willi Syndrome Data
Soleno announced promising results of its diazoxide choline extended-release tablets in patients with Prader-Willi syndrome at ENDO 2022.
June 14, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Versanis Hopes to Compete with Lilly, Novo in Weight Loss Space
Versanis Bio’s data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.
June 13, 2022
 · 
3 min read
 · 
Tristan Manalac
Tahi Ahmadi/both courtesy of Genmab
Drug Development
AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Genmab’s Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
June 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Abbvie Inc.
Business
AbbVie Touts New Data for Rare Blood Cancer & Leukemia Treatments
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
June 10, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More